What Has Been the Growth of the Diabetic Macular Edema DME Market So Far?
The diabetic macular edema dme market has seen considerable growth due to a variety of factors.
• In recent times, the diabetic macular edema (DME) market has witnessed a continuous growth. From a size of $4.67 billion in 2024, it is projected to increase to $4.89 billion in 2025, indicating a compound annual growth rate (CAGR) of 4.7%.
The causes for this expansion during the historical phase can be traced back to the increasing cases of diabetes, the rise in disorders related to edema, an upsurge in the occurrence of diabetic eye diseases, a surge in the old age population, and a rise in cases of blindness.
How Will the Diabetic Macular Edema DME Market?
The diabetic macular edema dme market is expected to maintain its strong growth trajectory in upcoming years.
• The forecast for the diabetic macular edema (DME) market suggests persistent growth in coming years, aiming to reach the $5.82 billion mark by 2029 with a compound annual growth rate (CAGR) of 4.4%.
The upsurge anticipated during the forecast period is driven by factors such as improved healthcare access, increased government funding for healthcare, growing awareness of diabetic problems, greater use of telemedicine for ophthalmological services, and enlarging network of dedicated diabetes eye care centers. Prevailing trends during the forecast period include the advent of anti-VEGF therapies, the use of corticosteroid implants, progress in drug administration systems, breakthroughs in retinal laser procedures, AI-backed diagnostic tools, and the trend towards adopting minimally invasive surgical methods.
Which Factors Are Boosting Growth In The Diabetic Macular Edema DME Market?
The upward trend of diabetes incidence is anticipated to propel the progression of the diabetic macular edema (DME) market in the future. The surge in diabetes incidence can be accredited to elements such as inactive lifestyles, poor dietary practices, escalating obesity figures, maturing demographics, and genetic susceptibility. Diabetic macular edema is a consequence of diabetes, which inflicts damage to the retinal blood vessels, triggers fluid leakage into the macula, causing swelling. For example, the Institute for Health Metrics and Evaluation, a research institute based in the US, unveiled in June 2023 that over half a billion people around the world were afflicted with diabetes. Predictions suggest that this figure will more than double, approximating 1.3 billion people by 2050. Thus, the accelerating frequency of diabetes is stimulating the expansion of the diabetic macular edema (DME) market.
What Key Areas Define The Segmentation Of The Global Diabetic Macular Edema DME Market?
The diabetic macular edema (DME) market covered in this report is segmented –
1) By Treatment: Anti-VEGF Therapy, Corticosteroids, Laser Therapy, Surgical Intervention
2) By Disease Stage: Early Stage, Moderate Stage, Advanced Stage
3) By Patient Demographics: Adults, Elderly, Children
4) By Route Of Administration: Intravitreal Injection, Topical, Systemic
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Anti-VEGF Therapy: Monoclonal Antibodies, Recombinant Protein-Based Therapies
2) By Corticosteroids: Intravitreal Steroid Injections, Injectable Sustained-Release Corticosteroids
3) By Laser Therapy: Focal Laser Photocoagulation, Panretinal Photocoagulation
4) By Surgical Intervention: Vitrectomy, Membrane Peeling
Pre-Book The Diabetic Macular Edema DME Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Diabetic Macular Edema DME Market?
Prominent entities in the Diabetic Macular Edema (DME) treatment arena are shifting their concentration towards technological evolutions, such as sophisticated drug therapies, to augment patient management and treatment results. These avant-garde treatments leverage recent technological breakthroughs and research to enhance the handling of complex medical conditions, focusing on bolstering efficacy, minimizing side effects, and yielding improved results for patients. Illustrating this, in March 2022, Novartis AG, a pioneering pharmaceutical company based in Switzerland, proclaimed the grant of approval by the European Commission for Beovu, a new treatment for visual impairment connected to DME. This green light stemmed from the outcomes of Phase III KESTREL and KITE studies, denoting comparable performance of Beovu to aflibercept in enhancing vision over the course of a year. Remarkably, more than half of the patients treated with Beovu adhered to a 12-week therapy regime and displayed fewer incidents of retinal fluid as opposed to those treated with aflibercept.
Who Are the Key Players In The Diabetic Macular Edema DME Market?
Major companies operating in the diabetic macular edema (DME) market are:
• Pfizer Inc.
• Johnson & Johnson
• F. Hoffmann-La Roche AG
• Merck & Co. Inc.
• Bayer AG
• Novartis AG
• Boehringer Ingelheim International GmbH
• Regeneron Pharmaceuticals
• Carl Zeiss Meditec AG
• Bausch & Lomb
• Santen Pharmaceutical Co. Ltd.
• Carl Zeiss AG
• Topcon Corporation
• Ypsomed AG
• ARKRAY Inc
• Hugel Inc.
• Optos plc
• Noven Pharmaceuticals Inc.
• Alimera Sciences Inc.
• Allergan plc.
What Is The Most Dominant Region In The Diabetic Macular Edema DME Market?
North America was the largest region in the diabetic macular edema (DME) market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic macular edema (DME) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
